Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: this medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original PMA or panel track supplement and may not represent the most recent labeling.
 
DeviceMINIMED 530G SYSTEM
Generic NameAutomated insulin dosing , threshold suspend
ApplicantMEDTRONIC Inc.
18000 DEVONSHIRE STREET
NORTHRIDGE, CA 91325-1219
PMA NumberP120010
Date Received06/05/2012
Decision Date09/26/2013
Product Code OZO 
Docket Number 13M-1206
Notice Date 09/30/2013
Advisory Committee Clinical Chemistry
Clinical TrialsNCT01112696
Expedited Review Granted? Yes
Combination ProductNo
RecallsCDRH Recalls
Approval Order Statement  
APPROVAL FOR THE MINIMED 5300 SYSTEM. THIS DEVICE IS INDICATED FOR THE FOLLOWING:MINIMED 530G SYSTEM - THE MINIMED 530G SYSTEM IS INTENDED FOR CONTINUOUS DELIVERY OF BASAL INSULIN (AT USER SELECTABLE RATES) AND ADMINISTRATION OF INSULIN BOLUSES (IN USER SELECTABLE AMOUNTS) FOR THEMANAGEMENT OF DIABETES MELLITUS IN PERSONS, SIXTEEN YEARS OF AGE AND OLDER, REQUIRING INSULIN AS WELL AS FOR THE CONTINUOUS MONITORING AND TRENDING OF GLUCOSE LEVELS IN THE FLUID UNDER THE SKIN. THE MINIMED 530G SYSTEM CAN BE PROGRAMMED TO AUTOMATICALLY SUSPEND DELIVERY OF INSULIN WHEN THE SENSOR GLUCOSE VALUE FALLS BELOW A PREDEFINED THRESHOLD VALUE. FOR ADDITIONAL INFORMATION PLEASE REFER TO APPROVAL ORDER.
Approval OrderApproval Order
SummarySummary of Safety and Effectiveness
LabelingLabeling
Post-Approval StudyShow Report Schedule and Study Progress
Supplements:  S001 S002 S003 S004 S005 S006 S008 S009 S010 S011 S012 
S013 S014 S015 S016 S017 S019 S020 S021 S022 S023 S024 S025 
S026 S027 S028 S029 S030 S031 S032 S033 S034 S035 S036 S037 
S038 S039 S040 S041 S042 S043 S045 S046 S047 S048 S049 S050 
S051 S052 S053 S054 S055 S056 S057 S058 S059 S060 S061 S062 
S063 S064 S065 S066 S067 S068 S069 S070 S071 S072 S073 S074 
S075 S076 S077 S078 S079 S080 S081 S082 S083 S084 S085 S086 
S087 S088 S089 S091 S092 S093 S095 S097 S098 S099 S100 S101 
S102 S103 S104 S105 S106 S107 S108 S109 S110 S111 S112 S113 
S114 S115 S116 S117 S118 S119 S120 S121 S122 S123 S124 S125 
S126 S128 S129 S131 S132 S133 S134 S135 S136 S137 S138 S139 
S140 S141 S142 
-
-